|
注册号: Registration number: |
ChiCTR2000030936 |
|
最近更新日期: Date of Last Refreshed on: |
2020-03-23 14:45:26 |
|
注册时间: Date of Registration: |
2020-03-18 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
请尽快上传伦理审批文件。 成都中医药大学附属医院联合开展医院制剂“银翘藿朴退热合剂(新冠2号)、荆防藿朴解毒合剂(新冠3号)”治疗新型冠状病毒肺炎(COVID-19)临床疗效评价的真实世界研究 |
|
Public title: |
A real-world study for the Chinese medicines ''Xinguan 2'' and ''Xinguan 3'' in the treatment of novel coronavirus pneumonia (COVID-19) |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
成都中医药大学附属医院联合开展医院制剂“银翘藿朴退热合剂(新冠2号)、荆防藿朴解毒合剂(新冠3号)”临床疗效评价的真实世界研究 |
|
Scientific title: |
Hospital of Chengdu University of Traditional Chinese Medicine jointly launched a real-world study on the clinical efficacy evaluation of the Inner hospital preparation |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
ChiMCTR2000003149 |
|
申请注册联系人: |
孔晓岚 |
研究负责人: |
高培阳 |
|
Applicant: |
Xiaolan Kong |
Study leader: |
Peiyang Gao |
|
申请注册联系人电话: Applicant telephone: |
+86 13693438696 |
研究负责人电话:
Study leader's |
+86 18980025566 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
394731278@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
gaopy930@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
成都市金牛区十二桥路39号 |
研究负责人通讯地址: |
成都市金牛区十二桥路39号 |
|
Applicant address: |
39 Shi-er-qiao Road, Chengdu, Sichua, China |
Study leader's address: |
39 Shi-er-qiao Road, Chengdu, Sichua, China |
|
申请注册联系人邮政编码: Applicant postcode: |
610072 |
研究负责人邮政编码: Study leader's postcode: |
610072 |
|
申请人所在单位: |
成都中医药大学附属医院 |
||
|
Applicant's institution: |
Hospital of Chengdu University of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
成都中医药大学附属医院 |
||
|
Affiliation of the Leader: |
Hospital of Chengdu University of Traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2020QKL-009 |
伦理委员会批件附件: Approved file of Ethical Committee: |
|
|
批准本研究的伦理委员会名称: |
四川中医药区域伦理审查委员会 |
||
|
Name of the ethic committee: |
Sichuan Traditional Chinese Medicine Regional Ethics Review Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-03-09 00:00:00 | ||
|
伦理委员会联系人: |
何清 |
||
|
Contact Name of the ethic committee: |
Qing He |
||
|
伦理委员会联系地址: |
四川省成都市成都中医药大学附属医院伦理审查办公室 |
||
|
Contact Address of the ethic committee: |
Ethics Review Office, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, 39 Shi-er-qiao Road, Chengdu, Sichua, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
成都中医药大学附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Hospital of Chengdu University of Traditional Chinese Medicine. |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
成都市金牛区十二桥路39号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
39 Shi-er-qiao Road, Chengdu, Sichua, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-financing |
||||||||||||||||||||||
|
研究疾病: |
新型冠状病毒肺炎(COVID-19) |
||||||||||||||||||||||
|
Target disease: |
Novel Coronavirus Pneumonia (COVID-19) |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
治疗研究 |
||||||||||||||||||||||
|
Study type: |
Treatment study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
半随机对照 |
||||||||||||||||||||||
|
Study design: |
Quasi-randomized controlled |
||||||||||||||||||||||
|
研究目的: |
评价医院制剂“银翘藿朴退热合剂(新冠2号)”、“荆防藿朴解毒合剂(新冠3号)”治疗新型冠状病毒肺炎临床疗效和安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
Evaluate the clinical efficacy and safety of the hospital preparations "Yinqiaohuopu Tuire Mixture (Xinguan No. 2)" and "Jingfanghuopujiedu Mixture (Xinguan No. 3)" in the treatment of new coronavirus pneumonia. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1)已知对本研究药物组成成份过敏; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Known allergies to the components of this study; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-03-10 00:00:00至 To 2020-05-10 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2020-03-10 00:00:00 至 To 2020-05-10 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究采用静态区组随机方法,中心以及分层分配入组, 采用CIMS随机系统进行随机。符合入排标准的受试者, 按照中医辨证证型(风热/风寒)进行分层。 采用中心下分层中每 N 个受试者编号为 1 个区组。受试者编号格式为□□□□, 为 4 位数字,表示受试者随机号,如 0001。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
In this study, a static block randomization method was used. Subjects who met the inclusion criteria were stratified according to TCM syndrome type (wind heat / wind cold). Each N subjects in the subcenter stratum were numbered as 1 block. The subject number format is □□□□, which is a 4-d |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
论文支持材料 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
surpporting materials for the artical. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |